Karen Sims - 10 Jul 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Medical Officer
Signature
/s/ David C. Hastings as attorney-in-fact for Karen Sims
Issuer symbol
ABUS
Transactions as of
10 Jul 2023
Net transactions value
$0
Form type
4
Filing time
12 Jul 2023, 16:50:46 UTC
Next filing
05 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +153,640 $0.000000 153,640 10 Jul 2023 Common Shares 153,640 $2.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.